Aspen, Adcock Ingram and other South African generic drugmakers stand to benefit from the introduction of a more efficient regulator and retailer Clicks’s expansion plans, BMI Research said in a note released on Wednesday. BMI estimated generic drugs sales in SA totalled R16.2bn in 2016, and expected this to grow to R40bn by 2026, equating to a compound annual growth rate of 9.5%. This growth will partly be thanks to the South African Health Products Regulatory Agency (Sahpra) replacing the Medicines Control Council (MCC) in April — if government meets its deadline. The new regulator’s first task will be to clear the backlog of 2,900 applications awaiting registration by the MCC. "The launch of Sahpra will see generic products being fast-tracked and brought to market much sooner than before, making newer generation molecules available to patients at a fraction of the cost," the report quotes Pharma Dynamics’ CEO Erik Roos saying. But BMI’s report noted that the establishment of Sahp...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.